spacer
home > ebr > Spring 2014
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2014

   
Text
PDF
Editor’s Letter

Promising developments are springing up across biopharma – Deborah O’Neil outlines some of the advances in R&D and biotechnology that emerge in this edition.
 
view
download pdf
bullet
BioResearch and Innovation
Cell-Based Therapies

Back to the Future


They may be an emerging niche within biopharma, but cell-based therapies are enjoying a steep growth trajectory. R Lee Buckler at Cell Therapy Group, and BioCision’s Rolf Ehrhardt and Maria Thompson outline the new technologies in this area.


 
view
download pdf
Regenerative Medicine

A New Dimension


As we enter a new pluripotent era of stem cell research, scientists are starting to take advantage of 3D printing technology to produce customised, cutting-edge prosthetics. Regina Au from BioMarketing Insight welcomes the revolution and predicts an exciting future.


 
view
download pdf
Culturing Cells

Controlled Environment


Sample security, culture efficiency and minimising contamination risk are essential when it comes to culturing cells. Jacqueline van der Zijden of Panasonic Biomedical describes how advances are helping to ensure reliability in the lab.
 
view
download pdf
BioDevelopment
Inter-Species Safety

Advancing Xenogeneic Therapy

Peter Gaskin and Kathryn Parsley from PPD examine the growing body of work on the non-clinical testing strategies for xenogeneic products, enabling the safe progression of products from animal models into clinical studies.

 
view
download pdf
Neutron Crystallography

In the Spotlight


Matthew Blakeley from the Institut Laue-Langevin explores how the combined use of X-rays and neutron crystallography is well-suited to drug development, as a recent study of interactions between a common clinical inhibitor and HIV-1 protease demonstrates.
 
view
download pdf
bullet
Legal, Regulatory and Public Policy
Controlled Substances

Chemical Weapons

Cheminformatics applications now being developed can aid researchers in complying with the global plethora of controlled substances regulations. Aurora Costache and Krisztian Niesz at ChemAxon set out some of the features and functionalities.
 
view
download pdf
bullet
THERAPEUTICS FOCUS - VACCINES AND INFECTIOUS DISEASES
Vaccine Production

Taking the Strain


The rapidly expanding demand for vaccine products for viral diseases such as rabies has prompted more sophisticated production techniques based around cell culture systems. K John Morrow, Jr, at Newport Biotech and Ma Sha at Eppendorf, Inc explain.
 
view
download pdf
BioManufacturing
Early-Phase Manufacturing

Fast and Flexible

To ensure Phase 1 oral solid dosage formulations are fit for purpose, early-stage manufacturers need approaches that are quick, adaptable and appropriate to the API in question. Jon Sutch at Patheon considers the systems needed.

 
view
download pdf
Protein Therapeutics

Flexibility in Bioprocessing

Adaptability is the name of the game in bioprocessing, with advances in cell culture, equipment, separation technologies and plastics applications enabling great strides in the production of a broad range of protein therapeutics, says Michiel E Ultee of Gallus BioPharmaceuticals.
 
view
download pdf
bullet
CANCER FOCUS
Antibody Engineering

Next-Generation ADCs

As we learn more about antibody drug conjugates, one of the key features for clinical success – and regulatory approval – will be the ability to control the conjugation process to optimise efficacy and safety, as well as to reduce toxicity risk, comments Neil Butt at PolyTherics.
 
view
download pdf
Tumour Modelling

Imaging of Relevance

The blending of developments in tumour models and imaging technologies is enabling efficient and robust use of the most clinically relevant and predictive models, argue Dick Leopold and Patrick McConville of Molecular Imaging, Inc.
 
view
download pdf
HPV-Related Cancers

Infection Control

With more HIV-positive individuals facing a growing risk of HPV-related cancers, Eyal Talor at CEL-SCI Corporation stresses the need for further research, such as a recent study looking at immunotherapy against AIN in co-infected subjects.
 
view
download pdf
bullet
REGIONAL UPDATES
Regional Development: Russia

Home Advantage


In a bid to reverse its reliance on imported pharmaceutical products, Russia is boosting the domestic development and manufacturing of innovative drugs through homegrown start-ups and investment. Maria Bomer from Bomer Pharma Consultancy explains.


 
view
download pdf
In Brief

Follow the Money

Emile Bellott explores the rising tide of biomedical R&D in East Asia – and how it may impact future generations of biotech companies.
 
view
bullet
INTERVIEW
Industry Interview

Human Impact


Octapharma’s Stefan Wietek talks to EBR about the intricacies of developing human proteins and the global demands facing the plasma industry.
 
view
download pdf
bullet
BUSINESS STRATEGY
Bioclusters

Group Dynamics


Many small and medium enterprises in the biopharma space are working in clusters to exploit the benefits of a supportive business ecosystem. CEBR’s Claire Skentelbery, Fabrizio Conicella at Bioindustry Park Silvano Fumero and BioWin’s Frédéric Druck report.
 
view
download pdf
Biotech Investment

Going Public


2013 was the most active year so far for initial public offerings of life sciences companies – and the biotech bonanza is set to continue this year. It can be a great route to success, but Sophie C McGrath of Brown Rudnick urges firms to consider some critical issues before going public.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July, and October

News and Press Releases

Sphere Fluidics expands into additional facility at Granta Park in Cambridge, UK

• New offices at leading science hub support the Company’s rapid growth following recent investment • New facility is in addition to headquarters at Babraham Research Campus, Cambridgeshire, UK and offices in Monmouth Junction, New Jersey, USA
More info >>

White Papers

Running Better Trials Taking an Intelligent Monitoring Approach

Bioclinica

When it comes to implementing a risk-based monitoring program, it is not just about reducing monitoring visits and doing less Source Document Verification (SDV). It’s about bringing together your people, a solid process, and the right technology to run a better trial. Success with risk-based monitoring requires the ability to make sense of the thousands, if not millions, of data points captured by multiple disparate sources in a clinical trial. With the sheer volume of data generated on a daily basis comes complexity. How does one make sense of it all? Information overload burdens even the most experienced study teams who struggle to understand which data matters most and what it means.
More info >>

Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement